Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Main Street, 14Th Floor CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://www.blackdiamondtherapeutics.com |
IR: | See website |
Key People | ||
Mark A. Velleca Chairman of the Board, President, Chief Executive Officer | Elizabeth Buck Co-Founder, Chief Scientific Officer | Fang Ni Chief Financial Officer, Chief Business Officer |
Brent M. Hatzis-Schoch Chief Operating Officer, General Counsel | Elizabeth L. Montgomery Chief People Officer | Erika Jones Vice President - Finance, Corporate Controller | Sergey Yurasov Chief Medical Officer |
Business Overview |
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company's MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene. |
Financial Overview |
For the fiscal year ended 31 December 2023, Black Diamond Therapeutics Inc revenues was not reported. Net loss decreased 10% to $82.4M. Lower net loss reflects Research and development (inclusive decrease of 5% to $56.3M (expense), Other income (expense) increase from $354K (expense) to $2.1M (income), Equity in losses of unconsolidated entit decrease from $2.3M (expense) to $0K. |
Employees: | 54 as of Feb 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $163.39M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$86.02M as of Dec 31, 2023 |
Net annual income (TTM): | -$82.44M as of Dec 31, 2023 |
Free cash flow (TTM): | -$66.75M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 51,717,849 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |